Introduction {#section6-0269881119858306}
============

Autism spectrum disorder (ASD) is a common ([@bibr5-0269881119858306]) and complex neurodevelopmental psychiatric condition, which shortens life expectancy by up to 20 years ([@bibr23-0269881119858306]). Moreover, 70% of autistic individuals are estimated to have co-occurring conditions, e.g. epilepsy ([@bibr45-0269881119858306]) and mood and anxiety disorders ([@bibr24-0269881119858306]). However, there are no effective pharmacological treatments for the core symptoms of ASD, and individuals often respond poorly to conventional treatments of complicating mental or physical illnesses. Alternative treatment approaches, such as cannabis and its major non-intoxicating component cannabidiol (CBD) ([@bibr17-0269881119858306]), are therefore increasingly explored.

There is accumulating evidence for the efficacy of CBD in several conditions, such as spasticity in multiple sclerosis ([@bibr51-0269881119858306]) and schizophrenia ([@bibr10-0269881119858306]); and in conditions associated with ASD, including social phobia ([@bibr8-0269881119858306]) and epilepsy ([@bibr14-0269881119858306]). Moreover, there are preliminary reports of beneficial effects of medical marihuana in idiopathic ASD itself ([@bibr3-0269881119858306]; [@bibr11-0269881119858306]). For instance, a recent study has demonstrated that CBD-rich cannabis reduced behavioural outbreaks in children with ASD and severe behavioural problems ([@bibr3-0269881119858306]). Thus, a role for CBD in ASD management warrants further attention. Consequently, there are now at least two clinical trials of CBD in ASD (clinicaltrials.gov; identifiers NCT03900923 and NCT02956226). However, we still have only limited understanding of how the typical human brain, let alone the autistic brain, responds to CBD. Hence, a fuller understanding of the mechanism of action of CBD on the brain, and its relevance to ASD, is desirable before investing in large-scale clinical trials.

Brain responsivity to pharmacological challenges can, for example, be measured using functional magnetic resonance imaging (fMRI) ([@bibr9-0269881119858306]; [@bibr19-0269881119858306]; [@bibr21-0269881119858306]). Evidence that such approaches are sensitive to CBD effects comes from studies in both neurotypicals and individuals with schizophrenia. For instance, in neurotypicals, CBD reduced fronto-striatal -- and decreased mediotemporal-prefrontal -- FC during a visual oddball salience task, and enhanced salience processing ([@bibr9-0269881119858306]). In neurotypicals, CBD also disrupted prefrontal-subcortical connectivity during the processing of fearful faces ([@bibr19-0269881119858306]), and increased fronto-striatal activity at rest ([@bibr21-0269881119858306]). In schizophrenia, an acute dose of CBD was reported to 'normalize' brain activity in regions during a verbal learning paradigm ([@bibr10-0269881119858306]). Similarly, fMRI has been used as a marker for other drug challenges in ASD, such as riluzole, propranolol or oxytocin ([@bibr1-0269881119858306]; [@bibr20-0269881119858306]; [@bibr38-0269881119858306]). However, the vast majority of these previous studies acquired fMRI during cognitive tasks.

Although this approach provides valuable task-specific information, it constrains the analysis of drug response to task-relevant brain regions (and so misses the potential impact of a drug on whole-brain function). Moreover, in a condition like ASD, where the performance of such higher cognitive tasks can be compromised (e.g. [@bibr4-0269881119858306]; [@bibr13-0269881119858306]), disentangling the effects of a drug from the demands of the task can be challenging. Thus, to examine whole-brain impact of CBD in individuals with and without ASD, we elected to use a resting state design.

In this randomised, placebo-controlled, double-blind, cross-over study we adopted a whole-brain, task-free (resting state) design to compare brain response to CBD in individuals with and without ASD. We used resting state fMRI to examine the fractional amplitude of low-frequency fluctuations (fALFF) (0.01−0.1 Hz) as a measure of spontaneous regional brain activity ([@bibr12-0269881119858306]). These low-frequency oscillations are thought to subsequently support the synchronisation of activity between spatially distinct regions (i.e. functional connectivity, FC) ([@bibr18-0269881119858306]). Therefore, in regions where a significant shift in fALFF was observed, we also conducted a secondary seed-based analysis of FC of that region with the rest of the brain. Data were acquired following a single oral dose of 600 mg CBD or a matched placebo (at least 13 days apart). We predicted that CBD would alter regional fALFF and also shift FC of those regions which responded. Moreover, based on our previous findings that the autistic brain responds atypically to pharmacological challenge ([@bibr1-0269881119858306]), we expected that responsivity to CBD would be different in autistic compared to neurotypical individuals.

Materials and methods {#section7-0269881119858306}
=====================

Procedure {#section8-0269881119858306}
---------

This research was conducted in accordance with the Declaration of Helsinki, at the Institute of Psychiatry, Psychology and Neuroscience at De Crespigny Park, SE5 8AF, London, UK (August 2016 to February 2017). Ethical approval for this study was provided by the King's College London Research Ethics Committee, study reference HR15/162744. All participants provided written informed consent. Every participant took part in all aspects of this case--control observational study. The Medicines and Health Research Authority in the UK confirmed that our study design is not a clinical trial; however, in the interests of transparency this observational study was registered on clinicaltrials.gov (identifier: NCT03537950, entry name: HR15-162744).

This was a placebo-controlled, randomised, double-blind, repeated-measures, cross-over study conducted as part of a larger investigation into the role of phytocannabinoids in ASD. Drugs were allocated in a pseudo-randomised order, so that each participant received each drug (PLC, CBD) once; approximately half of our participants attended a placebo visit before CBD; and half received CBD before placebo. This randomisation was implemented by G.M.M. using <https://www.random.org/>. Participants and those assessing outcomes were blinded to the assignment. Participants attended for two visits. To allow for drug wash-out, visits were separated each by a minimum of 13 days, with all attempts made to keep between-visit time consistent across all visits and participants. Moreover, time of data acquisition from both groups was largely overlapping. On each visit, urine samples were taken to screen for illicit substances (a full list is included below). Subsequently, participants underwent a brief health check and received a liquid oral dose of the pharmacological probe (600 mg of CBD or a matched placebo, both provided by GW Research Ltd, Cambridge, UK). The dose of 600 mg of CBD has previously been demonstrated to be sufficient to elicit an effect on brain in adults (e.g. [@bibr9-0269881119858306]), while being very well tolerated (GW Pharmaceuticals Investigator Brochure 2015). After a second brief health check to test for potential acute adverse reactions/side effects, participants underwent scanning timed to coincide with peak plasma (2 h) concentration. Following the scan, participants received a third health check to ensure they had experienced no ill-effects and were fit to leave the department.

Participants {#section9-0269881119858306}
------------

Potential participants were excluded if they had a comorbid major psychiatric or medical disorder affecting brain development (e.g. schizophrenia or epilepsy), a history of head/brain injury, a genetic disorder associated with ASD (e.g. tuberous sclerosis or Fragile X syndrome), an IQ below 70, or were reliant on receiving regular medication known to modulate directly the neurotransmitters glutamate and GABA. However, we included participants on other medications which are frequently prescribed in this condition. Thus, one autistic participant received a single dose of Ritalin on the morning of each test day, and another autistic participant took a single dose of sertraline on the morning of each visit. All participants were asked to abstain from using cannabis and/or other illicit substances in the month prior to scanning, and from drinking alcohol on the day prior to testing. Moreover, data from individuals who screened positive for illicit substances in the urine drug screening were excluded. Thus, we retained data from 34 subjects (17 neurotypicals, 17 ASD) (see [Table 1](#table1-0269881119858306){ref-type="table"} for demographics). All participants in the ASD group had a clinical diagnosis of ASD made according to ICD10 research criteria, supported by the use of standardised research diagnostic instruments (Autism Diagnostic Observation Schedule, ADOS; and Autism Diagnostic Interview-Revised, ADI-R) ([@bibr30-0269881119858306]; [@bibr31-0269881119858306]; [@bibr48-0269881119858306]).

###### 

Participant demographics for all subjects including standard deviations.

![](10.1177_0269881119858306-table1)

  Variable (SD)   Neurotypicals   ASD            *F*(dof)         *p*
  --------------- --------------- -------------- ---------------- -------------
  ***N* (M/F)**   17 (17/0)       13 (13/0)      ---              ---
  **Age (yr)**    28.47 (6.55)    30.85 (9.79)   *F*(1) = 0.634   *p* = 0.443

ASD: autism spectrum disorder; F: female; F(dof): *F* statistic and degrees of freedom; FSIQ: full-scale intelligence quotient; M: male.

Imaging data acquisition {#section10-0269881119858306}
------------------------

We acquired all imaging data on a 3T GE Excite II magnetic resonance imaging (MRI) scanner (GE Medical Systems, Milwaukee, WI, USA). Our scanning protocol included a structural MRI scan acquired using a 3D inversion recovery prepared fast spoiled gradient recalled (IR-FSPGR) sequence (slice thickness = 1.1 mm, spatial positions = 124, flip angle = 20°, field of view (FoV) = 280 mm, echo time (TE) = 2.844 ms, repetition time (TR) = 7.068 ms, inversion time (TI) = 450 ms, matrix = 256×256). This structural MRI scan was used for co-registration of the functional volumes. The scanning protocol further included a resting state MRI scan. This scan was acquired using an echo-planar imaging (EPI) sequence (slice thickness = 3 mm, slice gap = 3.3 mm, flip angle = 75°, FoV = 240 mm, TE = 30 ms, TR = 2000 ms, TI = 0 ms). We collected data for 256 time points, i.e. the resting state scan lasted 512 s.

Urine test {#section11-0269881119858306}
----------

We performed liquid chromatography-mass spectrometry (LC-MS) analysis on urine samples provided by each participant before the drug administration to test for the presence or absence of illicit substances that could confound potential effects of the pharmacological probes tested here. Participants showing positive results for any of the drugs tested, including amphetamines (amphetamine, methamphetamine, MDMA/Ecstasy), benzodiazepines, cannabis, cocaine (as benzoylecgonine), methadone and its metabolite EDDP, and opioids (6-monoacetylmorphine, morphine, codeine, dihydrocodeine), were excluded from the analysis. This resulted in the exclusion of four subjects (two neurotypicals, two ASD) from the original sample.

Data processing {#section12-0269881119858306}
---------------

### Structural data processing {#section13-0269881119858306}

T1-weighted structural MRI volumes were inspected manually to ensure adequate data quality and signal-to-noise ratio. Next, structural volumes were normalized to Montreal Neurological Institute (MNI) space, and segmented into grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF), to enable the removal of WM and CSF confounds using linear regression.

### Resting state data processing {#section14-0269881119858306}

We processed our resting state data using in-house software CONN v.17c ([@bibr47-0269881119858306]), DPABI v.2.1 ([@bibr49-0269881119858306]) and MATLAB R2017a (The MathWorks, Inc., MA, USREF). To ensure adequate data quality, all data were inspected manually for artefacts such as blurring, distortions, ghosting or warping. The first five functional volumes were discarded to allow for magnetization equilibrium.

Using CONN, all remaining functional volumes were slice-time corrected (sinc-interpolation), realigned (within runs to first volume, then all volumes to first volume of first run) and normalized to MNI space, using the segmented (into GM, WM and CSF) structural scans.

Head motion is thought to affect measures of FC ([@bibr42-0269881119858306]) and could potentially affect fALFF. To account for head motion, for each subject and run, we computed the frame-to-frame displacement (\>1.5 mm/° translation/rotation classified as motion outlier). Following previous studies (e.g. [@bibr20-0269881119858306]), we used a joint threshold, where subjects with movement in any dimension ⩾2 mm and/or ⩾15% of volumes identified as motion outliers were excluded from the analysis. This resulted in the exclusion of four runs from four subjects (all ASD). Thus, we retained a sample of 17 neurotypicals and 13 individuals with ASD.

#### fALFF data processing {#section15-0269881119858306}

Using DPABI, the functional data were detrended (linear trend removal), and denoised (WM, CSF and movement confounds removed through linear regression). Subsequently, the time series of each voxel was transformed into the frequency domain using a Fast Fourier transform (as described in [@bibr44-0269881119858306]. Next, we obtained the power spectrum and calculated the square root (amplitude) at each frequency of the power spectrum. The sum of amplitudes across the low-frequency spectrum (0.01 \< *f* \< 0.1 Hz) was divided by that across the entire frequency range (0 \< *fT* \< 0.25 Hz). Individual fALFF maps were then standardised (Z-value; subtraction of global mean, and division by standard deviation) within a brain mask (average GM mask across all subjects) and smoothed (using a Gaussian filter with a 6-mm full width at half maximum (FWHM) kernel). Thus, our analysis of low-frequency fluctuations proceeded on a voxel by voxel basis.

#### FC data processing {#section16-0269881119858306}

Using CONN, data were smoothed (using a 6-mm FWHM Gaussian kernel), detrended (linear trend removal), denoised (WM, CSF, realignment, and movement confounds removed through linear regression), and band-pass filtered.

In contrast to our fALFF analysis, our analysis of interregional FC used the average activity within predefined regions of interest (ROIs) based on standard whole-brain atlases provided by CONN. These FC measures reflect the correlations between pairs of discrete ROIs. We tested for experimental effects on the FC between key regions -- identified in the voxel-based analysis of low-frequency fluctuations - using standard analysis of variance.

Statistical analysis {#section17-0269881119858306}
--------------------

Demographic measures (age, IQ) were compared using a one-way ANOVA (significance level *p* \< 0.05).

We first compared baseline levels of fALFF within GM regions between groups using a two-sample *t*-test with non-parametric inference (Threshold Free Cluster Enhancement (TFCE), *p*~FWE~ \< 0.05) with 5000 permutations.

To test our primary hypothesis that CBD modulates fALFF within GM regions, we used a 2×2 factorial design with group (neurotypicals, ASD) as between-subject factor, drug (PLC, CBD) as within-subject factor, and regional fALFF as the dependent variable. We used non-parametric inference at a familywise error rate (FWE) *q* = 0.05 (5000 permutations) and TFCE. As outlined in the *Introduction*, we also wanted to examine the consistency of this response across groups and to establish if a CBD effect was indeed present within each group. Hence, in regions where we discovered a significant effect of drug, we performed planned post-hoc tests of these drug effects within each group separately using non-parametric inference (TFCE, *p*~FWE~ \< 0.05) with 5000 permutations.

Our secondary hypothesis was that CBD modulates FC between the regions identified in our fALFF analysis and the rest of the brain in ASD and neurotypicals. To this aim we conducted planned post-hoc tests within each group separately to examine potential effects of CBD on FC of those regions with the rest of the brain, using a seed-based repeated-measures design (connection-level threshold: *p*~uncorr~ = 0.05; seed-level threshold, using false discovery rate (FDR): *p*~FDR~ = 0.05).

All analyses were performed using SPSS 24.00 software (SPSS, Chicago, IL, USA), DPABI v.2.1 ([@bibr49-0269881119858306]) and CONN v.17c ([@bibr47-0269881119858306]).

Results {#section18-0269881119858306}
=======

Demographics {#section19-0269881119858306}
------------

Groups did not differ significantly in age (*F*(1) = 0.634, *p* = 0.443) or in full-scale IQ (*F*(1) = 3.230, *p* = 0.083). We observed no subjective or objective ill-effects/harm following administration of the study drug in any of our participants ([Table 1](#table1-0269881119858306){ref-type="table"}).

Fractional amplitude of low-frequency fluctuations (fALFF) {#section20-0269881119858306}
----------------------------------------------------------

There were no baseline group differences in fALFF within GM regions (TFCE, *p*~FWE~ \> 0.05); however, there was a main effect of drug. Across both groups, CBD (compared to PLC) increased fALFF in the cerebellar vermis VI (TFCE, *p*~FWE~ = 0.048, *k* = 4, centre of gravity in millimetres (CoG): *x* = −1, *y* = −65, *z* = −6) and in the right fusiform gyrus (TFCE, *p*~FWE~ = 0.041, *k* = 14, CoG: *x* = 28.9, *y* = −48.7, *z* = −6.86), as depicted in [Figure 1](#fig1-0269881119858306){ref-type="fig"}. There was no main effect of group, nor a drug × group interaction.

![Drug effects on the fractional amplitude of low-frequency fluctuations across the grey matter (cannabidiol *\>* placebo). Numbers above the slices indicate location in z-direction (in millimetres). Scans are oriented in neurological convention, where right (R) equals right, and left (L) equals left. *P* values (P), as indicated by the colour bar, are corrected for multiple comparisons (TFCE, FWE).](10.1177_0269881119858306-fig1){#fig1-0269881119858306}

Post-hoc within-group analyses confirmed a significant effect of drug in the ASD group (vermis VI: TFCE, *p*~FWE~ = 0.045, *k* = 7, CoG: *x* = 21.1, *y* = −55.7, *z* = −14; fusiform: TFCE, *p*~FWE~ = 0.029, *k* = 19, CoG: *x* = 28.3, *y* = −51.8, *z* = −9.58), but not in neurotypicals, as shown in [Figure 2](#fig2-0269881119858306){ref-type="fig"}.

![Post-hoc test of drug effects on the fractional amplitude of low-frequency fluctuations within each region of interest (cannabidiol \> placebo) in autism spectrum disorder. (A) Drug effects within the cerebellar vermis IV; (B) drug effects within the right fusiform gyrus. Numbers above the slices indicate location in *z*-direction (in millimetres). Scans are oriented in neurological convention, where right (R) equals right, and left (L) equals left. *P* values (P), as indicated by the colour bar, are corrected for multiple comparisons (TFCE, FWE).](10.1177_0269881119858306-fig2){#fig2-0269881119858306}

Functional connectivity (FC) {#section21-0269881119858306}
----------------------------

There were no baseline group differences in vermal or fusiform FC. In the ASD group, CBD significantly increased vermal FC with the left (*T*(11) = 2.57, *p* = 0.026) and right caudate (*T*(11) = 2.26, *p* = 0.045); and decreased vermal FC with the temporo-occipital part of the left middle temporal gyrus (*T*(11) = −2.81, *p* = 0.017), the right anterior supramarginal gyrus (*T*(11) = −2.73, *p* = 0.02), the left superior parietal lobe (*T*(11) = −2.54,*p* = 0.027) and the left superior frontal gyrus (*T*(11) = −2.29,*p* = 0.043). In contrast, CBD had no significant effect on vermal or fusiform FC with any other regions in the neurotypicals; but this between-group difference in responsivity was not significant. These findings are summarised in [Table 2](#table2-0269881119858306){ref-type="table"} and [Figure 3](#fig3-0269881119858306){ref-type="fig"}.

###### 

Drug effects on functional connectivity in the autism spectrum disorder (ASD) group.

![](10.1177_0269881119858306-table2)

  ------------------------------------------------------------------------------------------------------------------------
  Seed region                                 Contrast                       Target region   Statistic
  ------------------------------------------- ------------------------------ --------------- -----------------------------
  *Drug effect in ASD*                                                                       

  **Vermis VI**                               CBD \> PLC\                    R caudate       *T*(11) = 2.57, *p* = 0.026
                                              CBD \< PLC                                     

  L caudate                                   *T*(11) = 2.26, *p* = 0.045                    

  L temporo-occipital middle temporal gyrus   *T*(11) = −2.81, *p* = 0.017                   

  R anterior supramarginal gyrus              *T*(11) = −2.73, *p* = 0.020                   

  L superior parietal lobe                    *T*(11) = −2.56, *p* = 0.027                   

  R superior parietal lobe                    *T*(11) = −2.54, *p* = 0.027                   

  L superior frontal gyrus                    *T*(11) = −2.29, *p* = 0.043                   

  **Right fusiform**                          CBD \> PLC                     ---             n.s.

                                              CBD \< PLC                     ---             n.s.
  ------------------------------------------------------------------------------------------------------------------------

CBD: cannabidiol; L: left; n.s.: not significant; PLC: placebo; R: right.

![Drug effects on functional connectivity of cerebellar vermis VI in the ASD group (cannabidiol *\>* placebo). *T*-values (T) of edges, as indicated by colour bar, are corrected for multiple comparisons at connection- and seed-level (*p* = 0.05 and *p*~FDR~ = 0.05, respectively). Abbreviations -- ASD: autism spectrum disorder; CBD: cannabidiol; L.Caud: left caudate; L.SFG: left superior frontal gyrus; L.SPL: left superior parietal lobe; L.toMTG: left middle temporal gyrus (temporo-occipital part); R.aSMG: right anterior supramarginal gyrus; R.Caud: right caudate; R.SPL: right superior parietal lobe; PLC: placebo; Verm6: cerebellar vermis VI.](10.1177_0269881119858306-fig3){#fig3-0269881119858306}

Discussion {#section22-0269881119858306}
==========

Here we report, for the first time, that CBD 'shifts' fALFF and FC in the adult human brain. Specifically, we found that CBD significantly increased fALFF in the cerebellar vermis VI and the right fusiform gyrus. However, post-hoc within-group testing indicated that this shift was most prominent in ASD, and not significant in controls (please note that we did not identify a significant group by drug interaction). Moreover, in ASD, but not controls, the shift in fALFF in the cerebellum (but not fusiform gyrus) was accompanied by widespread changes in vermal FC with several of its subcortical and cortical targets.

Cerebellar vermis {#section23-0269881119858306}
-----------------

In the typical brain, the cerebellar vermis and its cerebellar--subcortical--cortical circuitry are increasingly understood to subserve a critical role in movement, language and social processing ([@bibr15-0269881119858306]). In ASD, however, there have been reports of functional anomalies in the cerebellum, which are thought to contribute to the disruption of these processes observed in ASD; but the results have been inconsistent.

For example, vermal hypoactivation during simple motor tasks (finger tapping) ([@bibr35-0269881119858306]) and during auditory perception (listening to tones) has been observed in adults with ASD ([@bibr34-0269881119858306]). In children and adolescents with ASD, FC of the vermis with sensorimotor regions has been reported to be higher; whereas vermal FC with prefrontal and motor regions has been recorded as lower ([@bibr27-0269881119858306]) compared to neurotypicals. Hence, the results of functional imaging studies in ASD may depend on the task under investigation. Here we used a non-task design and observed no baseline differences in cerebellar fALFF and FC measures (with other regions) in participants with and without ASD. Instead, we found that cerebellar activity and connectivity was modifiable, and especially so in ASD. Specifically, we found that the CBD-induced increase in vermal fALFF in ASD was accompanied by an increase in cerebellar--subcortical (striatal) FC. However, CBD also decreased cerebellar-cortical FC. This suggests that, in autistic adults, rather than inducing a general and unidirectional shift in FC, CBD appears to 'tune' FC in a region- or connection-specific manner. It was beyond the scope of the present study to examine the cognitive or behavioural implications of this response.

Right fusiform gyrus {#section24-0269881119858306}
--------------------

In the neurotypical brain, the right fusiform is commonly associated with the visual processing of words ([@bibr32-0269881119858306]) and parts of the body (vs objects), e.g. faces ([@bibr33-0269881119858306]). In ASD, face processing is overwhelmingly reported to be impaired ([@bibr4-0269881119858306]; [@bibr28-0269881119858306]), and this is consistent with a wealth of evidence for functional fusiform anomalies in this condition. For instance, neuroimaging studies have reported hypoactivation ([@bibr41-0269881119858306]) and impaired FC ([@bibr28-0269881119858306]) during face processing. Again, using a task-free design we found no baseline differences in the activity of this region; but our results indicate that CBD modulates fusiform activity, and that the ASD group was particularly responsive. Our study design does not speak to whether face processing in ASD would also be altered by CBD, but it does indicate that the functional dynamics of this region in ASD differ from controls, in that activity can be modulated by CBD.

Although CBD shifted fALFF in both the vermis 6 and right fusiform gyrus, it only altered FC of the vermis (and other regions) and not of the fusiform (and other regions) of individuals with ASD. The reason for this is not known. One explanation is that the connections of the fusiform with other regions are relatively limited, certainly compared to the cerebellum. Fusiform FC (with other regions) in ASD specifically may be further restricted by the anatomy of the fusiform region in this condition. For example, the grey-white matter boundary of the fusiform gyrus has been observed to be disrupted in ASD ([@bibr2-0269881119858306]), as has the integrity of WM tracts in this location ([@bibr6-0269881119858306]). Abnormalities in WM connections could restrict the impact of CBD on wider FC of this seed. In contrast, previous studies of the vermis indicate that the microstructural integrity of WM connections in this region is intact or even higher in ASD ([@bibr39-0269881119858306]; [@bibr7-0269881119858306]); and thus there may be more 'capacity' for FC of the cerebellum with other regions to change in response to pharmacological challenge in ASD

Neurobiological basis of CBD effects on fALFF and FC {#section25-0269881119858306}
----------------------------------------------------

The neurobiological underpinnings of these effects are unclear. However, previous studies indicate that CBD can influence excitatory glutamate and inhibitory GABA pathways, which play a crucial role in the regulation of LFF and FC ([@bibr16-0269881119858306]).

Preclinical studies suggest that CBD has a range of actions which may, for example, converge in a modulation of brain excitation and inhibition ([@bibr25-0269881119858306]; [@bibr37-0269881119858306]; [@bibr43-0269881119858306]). This is important because the balance of excitation and inhibition is postulated to help establish and maintain LFF and FC. Inhibitory phasic GABAergic interneurons, for instance, are key modulators of temporo-spatial signal integration and propagation. Through feed-forward inhibition, these neurons can synchronise large numbers of pyramidal cells and thus provide the basis for coordinated firing across distinct brain regions ([@bibr16-0269881119858306]). Similarly, tonic GABAergic neurons can shape LFF by tuning cell conductance and thus controlling the amount and duration of voltage response to excitatory input ([@bibr16-0269881119858306]). Several targets of CBD in the brain, e.g. TRPV1, GPR55 and 5-HT receptors, have been linked to brain glutamate and/or GABA signalling ([@bibr25-0269881119858306]; [@bibr37-0269881119858306]; [@bibr43-0269881119858306]) and so may impact upon this neural activity. For instance, TRPV1-activation through CBD has been reported to increase glutamatergic excitation ([@bibr37-0269881119858306]). In contrast, CBD antagonism on GPR55 has been observed to increase the firing of GABAergic interneurons ([@bibr25-0269881119858306]). Finally, CBD is an agonist on 5-HT~1A~ and 5-HT~2A~ receptors, which can be found both on excitatory and inhibitory neurons ([@bibr43-0269881119858306]); thus, CBD action through these receptors may both enhance and reduce excitatory and inhibitory transmission. In ASD, however, these targets of CBD have been reported to be altered (e.g. [@bibr26-0269881119858306]; [@bibr46-0269881119858306]). This may partly explain the differential findings in ASD compared to neurotypicals observed here.

An alternative explanation for the sensitivity of ASD and not controls to a drug challenge targeting glutamate-GABA systems may be the abnormalities in these systems -- and their responsivity -- in ASD. For instance, there is reduced expression of GABA receptors in the fusiform in ASD ([@bibr40-0269881119858306]). Similarly, decreased levels both of glutamic acid decarboxylase (the enzyme responsible for converting glutamate to GABA) and of inhibitory Purkinje cells in the vermis in ASD ([@bibr36-0269881119858306]; [@bibr50-0269881119858306]) suggest inhibition deficits in this condition. Thus, our results open the possibility that in ASD, CBD boosts LFF (and FC) especially in regions where GABA systems are impaired. This proposed link between the glutamate-GABA system and functional circuitry is supported by previous findings of a significant correlation between cerebellar excitation--inhibition levels and cerebro-cerebellar FC in adolescents and adults with ASD ([@bibr22-0269881119858306]).

Limitations {#section26-0269881119858306}
-----------

We acknowledge that our study has important limitations.

First, our study sample size was modest because: (a) we applied strict recruitment criteria (e.g. exclusion of candidates with comorbid psychiatric or medical conditions, which can be challenging in ASD); (b) participants were asked to adhere to time-intensive repeated testing over several weeks, involving drug administration -- this commitment was not always practical; and (c) we performed rigorous data quality control and excluded some datasets. Nonetheless, our repeated-measures design mitigated these constraints to some extent by reducing inter-subject variability (each participant had two scans and thus acted as their own 'control') and thus increasing statistical power. In addition, our findings survived rigorous statistical thresholding.

Second, fALFF analysis is focused on a single frequency range (0.01--0.1 Hz). However, in the human brain, a range of frequency bands are thought to interact and to possess hierarchical structure. For instance, EEG approaches have shown that delta (1--4 Hz) phase modulates theta (4--10 Hz) amplitude, and that theta phase modulates gamma (30--50 Hz) amplitude ([@bibr29-0269881119858306]). Future studies are required to investigate the impact of CBD across different frequency bands to obtain a more comprehensive view of CBD effects in the neurotypical and autistic brain.

Third, in the present study we investigated the impact of acute CBD administration. However, the effects of longer periods of treatment with CBD on fALFF and FC (and eventually on clinically relevant indices) are difficult to predict and may vary between individuals. Therefore, future studies are required to examine the effects of chronic CBD administration on brain, and whether the acute response to CBD may help predict the impact of sustained treatment.

Fourth, there are two qualifications that need to be considered when interpreting our results. These qualifications apply to most studies of resting state FC. The first pertains to the nature of resting state fMRI: by its nature, this task-free paradigm relinquishes experimental control over neuronal processing or attentional set. It is therefore possible that the differences we have observed reflected group differences in the way that subjects responded to the scanning experience. The second issue is specific to the way in which we quantified FC. By using the correlation coefficient as a measure of FC, we acknowledge that a significant effect on a correlation coefficient can be produced either by a change in the linear coupling between two regions, or by a difference in noise. In other words, an increase (or decrease) in the correlation coefficient can be explained by a decrease (or increase) in noise or random effects due to mental or other (e.g., motion) effects. In short, a difference in correlation can be explained either in terms of a difference in variance explained in one region by another region -- or by a difference in the variance not explained (i.e., noise). A more direct way to test for differences in linear coupling would have been to use a form of psychophysiological interaction in which the Fisher transformed correlation coefficients are replaced by the regression coefficients (obtained by regressing the activity of a target region on a source region). We will consider this in future work.

Conclusions {#section27-0269881119858306}
===========

In summary, we report the first evidence that CBD 'shifts' fALFF and associated FC in the adult autistic brain. Thus, in ASD, CBD can alter a crucial property of brain function, and targets key regions commonly implicated in the condition. Future studies are required to (a) investigate if CBD-induced alterations of fALFF and FC in ASD impact on the cognitive processes and behaviours these regions modulate; and (b) examine whether brain response to an acute dose of CBD may help predict response to sustained treatment in ASD.
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